Claire Mathiot
Overview
Explore the profile of Claire Mathiot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
3880
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, et al.
Lancet
. 2019 Jun;
394(10192):29-38.
PMID: 31171419
Background: Bortezomib, thalidomide, and dexamethasone (VTd) plus autologous stem-cell transplantation is standard treatment in Europe for transplant-eligible patients with newly diagnosed multiple myeloma. We evaluated whether the addition of daratumumab...
2.
Pertesi M, Vallee M, Wei X, Revuelta M, Galia P, Demangel D, et al.
Leukemia
. 2019 Apr;
33(9):2324-2330.
PMID: 30967618
No abstract available.
3.
Garderet L, Kuhnowski F, Berge B, Roussel M, Escoffre-Barbe M, Lafon I, et al.
Blood
. 2018 Oct;
132(24):2555-2563.
PMID: 30282798
It is important to have an effective therapy for patients with multiple myeloma (MM) at first relapse, particularly if an autologous stem cell transplant (ASCT) is considered at this stage....
4.
Fouquet G, Karlin L, Macro M, Caillot D, Roussel M, Arnulf B, et al.
Ann Hematol
. 2018 Jan;
97(5):831-837.
PMID: 29330561
The combination of pomalidomide and low-dose dexamethasone (Pom-Dex) has proved effective and safe in patients with end-stage relapsed/refractory multiple myeloma (RRMM), otherwise characterized by a very poor outcome. MM remains...
5.
Dubois C, Morin F, Moro-Sibilot D, Langlais A, Seitz J, Girault C, et al.
Bull Cancer
. 2017 Jul;
104(7-8):652-661.
PMID: 28688747
Introduction: The French Cancer Plan 2014-2019 stresses the importance of strengthening collaboration between all stakeholders involved in the fight against cancer, including cancer cooperative groups and intergroups. This survey aimed...
6.
Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al.
N Engl J Med
. 2017 Apr;
376(14):1311-1320.
PMID: 28379796
Background: High-dose chemotherapy plus autologous stem-cell transplantation has been the standard treatment for newly diagnosed multiple myeloma in adults up to 65 years of age. However, promising data on the...
7.
Sall A, Toure A, Sall F, Ndour M, Fall S, Sene A, et al.
BMC Hematol
. 2016 Apr;
16:10.
PMID: 27110362
Background: Chronic lymphocytic leukemia (CLL) is a mature B-cell neoplasm characterized by the expansion of CD5-positive lymphocytes in peripheral blood. While CLL is the most common type of leukemia in...
8.
Leleu X, Karlin L, Macro M, Hulin C, Garderet L, Roussel M, et al.
Blood
. 2015 Jan;
125(9):1411-7.
PMID: 25575538
The combination of pomalidomide and low-dose dexamethasone (Pom-Dex) can be safely administered to patients with end-stage relapsed/refractory multiple myeloma (RRMM). However, we observed a shorter median progression-free survival (PFS) and...
9.
Rodon P, Hulin C, Pegourie B, Tiab M, Anglaret B, Benboubker L, et al.
Haematologica
. 2014 Nov;
100(2):e56-9.
PMID: 25398832
No abstract available.
10.
Boyle E, Fouquet G, Guidez S, Bonnet S, Demarquette H, Dulery R, et al.
Cancer
. 2014 Aug;
120(24):3952-7.
PMID: 25116271
Background: Accurate quantification of immunoglobulin A (IgA) monoclonal immunoglobulins by serum protein electrophoresis (SPEP) can be difficult and can impact the assessment of response among patients with multiple myeloma (MM)....